B
lood-based biomarkers, including genomic, transcriptomic, proteomic, and other cellular components, are amenable to minimally invasive approaches for cancer detection and assessment (1) . Circulating tumor cells (CTCs), which are currently defined as epithelial cells in a cancer patient's bloodstream derived from tumor cell release, are an established prognostic blood biomarker, because their concentration in blood is associated with high tumor burden (2) . CTC gene expression and gene mutation profiling may therefore noninvasively recapitulate the primary and metastatic tumor composition, potentially yielding clinically actionable information. Therefore, CTC single-cell mutation analysis for clinical application may be a practical approach for tumor progression monitoring and treatment selection.
CellSearch is the only US Food and Drug Administrationapproved technology since its introduction in 1999 to identify CTCs in whole blood (3) . Many other innovative platforms (2) leverage various physical and biochemical properties of CTCs for highly sensitive and efficient enrichment (2) , encompassing improved epithelial cell adhesion molecule (EpCAM)-based capture [e.g., CTC Chip (4), HB-Chip (5), μNMR (6), MagSweeper (7) , and MagSifter (8) ], size-selective capture [e.g., Cluster-Chip (9), ISET (2, 10) , and Vortex technologies (11) ], inertial-based capture [e.g., iChip platform (12) ], nanomaterials-based capture [e.g., nanofilms (13) , NanoVelcro (14) , and functionalized graphene oxide nanosheets (15) ], and image-based cytometry [e.g., HD-CTC (16) ].
These current platforms, unfortunately, are overwhelmingly reliant on the enumeration of CTCs by immunocytochemistry (ICC) to measure tumor burden, which clearly does not probe underlying CTC tumor biology. To overcome limitations of existing CTC identification strategies, downstream analysis of individual CTCs via highly sensitive and specific single-cell measurements of tumor-derived blood components is imperative. Investigators have detected CTCs via gene expression directly from unprocessed whole blood (17, 18) , but these measurements are typically (i) obscured by background signals from circulating mRNA, white blood cells (WBCs), and other blood components (19) and (ii) performed using ensemble measurements that inadequately represent individual cell phenotypes. Because this analysis averages out signals across individual CTCs, the heterogeneity of different CTC populations is not detected, which could play a critical role in understanding a patient's tumor biology, metastatic potential, and
Significance
There exists an urgent need for minimally invasive molecular analysis tools for cancer assessment and management, particularly in advanced-stage lung cancer, when tissue procurement is challenging and gene mutation profiling is crucial to identify molecularly targeted agents for treatment. High-throughput compartmentalization and multigene profiling of individual circulating tumor cells (CTCs) from whole-blood samples using modular gene panels may facilitate highly sensitive, yet minimally invasive characterization of lung cancer for therapy prediction and monitoring. We envision this nanoplatform as a compelling research tool to investigate the dynamics of cancer disease processes, as well as a viable clinical platform for minimally invasive yet comprehensive cancer assessment.
clinical course (20) . Other reported methods for single-cell multigene expression CTC profiling of breast cancer (21) and metastatic prostate cancer (22) suffer from limited throughput-each captured cell is manually selected, lysed, and subjected to reverse transcription into cDNA before parallel multigene expression profiling, thus precluding their large-scale clinical application.
In particular, lung cancer presents an urgent need for a routine, minimally invasive clinical assessment tool, because (i) it is the leading cause of cancer deaths worldwide (23); (ii) many lung cancer patients are diagnosed at the most advanced stage; (iii) new molecularly targeted therapies are emerging to improve progression-free and overall survival for those patients with driver mutations such as epidermal growth factor receptor (EGFR) (24) and anaplastic lymphoma kinase (ALK) (25) ; (iv) new methods for diagnosis and treatment monitoring are imperative because accessing the primary tumor or metastatic lesions can be technically challenging, morbid, and costly; and (v) CTCs have been isolated and profiled for key driver mutations in non-small-cell lung cancer (NSCLC) (17) .
With the above needs in mind, we report the development, validation, and demonstrated clinical utility of an integrated nanoplatform that features a magnetic sifter [MagSifter (8) ] and singlecell nanowell array capable of sorting up to 25,600 cells [Nanowell (26, 27) ] to capture, easily compartmentalize, and molecularly characterize single CTCs from blood ( Fig. 1) . We report here a proof-of-concept demonstration showing single-CTC multigene expression and mutation profiling for tumor interrogation using four-plex modular gene panels, including panels for EGFR mutation detection for therapy prediction and monitoring.
Results
Overall Workflow. The Nanowell performs massively parallel sorting of individual CTCs into 25,600 separate compartments. First, the MagSifter technology (8) (Fig. 1 and Fig. S1 ) tags CTCs with magnetic nanoparticles for high-throughput, highefficiency CTC enrichment from blood. After MagSifter enrichment from 2-mL whole-blood samples (see Fig. S2 for illustration of captured cells via conventional ICC), red blood cells (RBCs) are hemolyzed (28) and DNase I is added to remove circulating genomic DNA, obtaining ultrapure cellular eluent that is seeded into Nanowell by direct pipetting and centrifugation. Single-cell multigene RT-PCR is performed with our modular multigene panels: a CTC identification panel with telomerase reverse transcriptase (TERT) (29, 30) and mesenchymal-epithelial transition (MET) (31, 32) to identify putative CTCs in advanced-stage NSCLC patients, and a therapy prediction and monitoring panel with TERT, an EGFR mutation, and its corresponding wild-type gene for identification and mutation detection of putative CTCs in advanced-stage NSCLC. NSCLC and noncancer cell lines were used to validate the gene expression panels on the integrated nanoplatform. To demonstrate its potential for clinical translation, samples from both healthy human subjects and patients diagnosed with NSCLC with the CTC identification panel (TERT and MET) were assayed. Subsequently, all eluent is directly loaded without staining onto a Nanowell device, and cells are seeded into individual compartments by centrifugation. After drying, single-cell RT-PCR mix is applied to the nanowells, which are then sealed with PCR tape. (C) The Nanowell device is then placed into a thermocycler for multiplex gene mutation and expression analysis via reverse transcription and PCR amplification. Multigene expression via up to four off-the-shelf hydrolysis probes with discrete emission spectra can be imaged in each nanowell. These fluorescence signals are then analyzed with custom MATLAB and R scripts for identification and characterization of putative CTCs based on modular panels of representative genes. These panels are flexible and can be adjusted to accommodate clinical needs such as therapy prediction and disease monitoring.
Then, therapy prediction and monitoring (TERT, EGFR mutant, and EGFR wild-type) panels were assayed using advanced-stage NSCLC patient blood samples.
Single-Cancer-Cell Detection Using the Nanowell Assay on Cell Lines.
We first identified mutations in HCC827 and H661 cell lines ( Fig.  2A) , which are mutant and wild type, respectively, for EGFR exon 19 deletion (del19) in bulk and then at the individual-cell level to demonstrate the utility of Nanowell. Bulk gene expression analysis of total mRNA extracted from 10 6 cells each of HCC827 and H661 indicated their mutually exclusive gene expression of EGFR E746-A750del [the most common del19 mutation (33) ] and wild type, respectively (P < 0.0001, two-sample t test). Nanowell confirmed differential del19 expression between HCC827 and H661, with individual HCC827 cells expressing only EGFR E746-A750del (green) and individual H661 cells exhibiting only wild-type EGFR (orange) (P < 0.0001) (Fig. 2B) .
We further examined the bulk gene expression of 10 6 cells each of five NSCLC cell lines (A549, H661, H1650, H1975, and HCC827), a noncancerous fibroblast (PCS-201) cell line, and WBCs from 2 mL of healthy human blood. Cancer cells expressed significantly higher TERT and MET than PCS-201 cells and WBCs (P < 0.0001, t test), both of which expressed no TERT and low MET (Fig. 2C) , thus implying that TERT and MET are good CTC markers.
We then assessed Nanowell's ability to distinguish between cancerous and noncancerous cells by differential gene expression profiling of H1650 and PCS-201 cell lines. H1650 and PCS-201 cells were stained with CellTracker Green CMFDA and Orange CMRA dyes (Life Technologies), respectively, and assayed together in a Nanowell for TERT. Nanowell images were acquired in three fluorescence channels corresponding to H1650 cells (as denoted in green color), PCS-201 cells (denoted as red color), and TERT gene expression (denoted as blue color) (Fig. 2D) . TERT expression signals revealed a significant differentiation between H1650 and PCS-201 cells (P < 0.0001, t test).
Four-Plex Gene Expression of Single H1650 Cells Spiked into Healthy Blood. To validate the suitability of a modular gene panel including vimentin (VIM) and aldehyde dehydrogenase (ALDH) in addition to TERT and MET for CTC identification, we examined the bulk gene expression of 10 6 cells from each of five NSCLC cell lines (A549, H661, H1650, H1975, and HCC827), a noncancerous fibroblast (PCS-201) cell line, and WBCs from 2 mL of healthy human blood. We noted heterogeneous VIM and ALDH expression across these cell types (Fig. S3) .
After performing these in vitro experiments, we assessed whether our platform could isolate cells spiked into healthy human blood using H1650 cells, which mimics the NSCLC patient condition (Fig. 3A) . After demonstrating bulk gene expression for our four-plex assay TERT, MET, VIM, and ALDH, we observed distinct patterns of gene expression on individual cells isolated from doped blood (Fig. 3B) . One cell population expressed high VIM only (Fig. 3 C, E, and F), which we attribute to WBCs' mesenchymal cell origin (34) , whereas the second cell population expressed high TERT, MET, and VIM, and variable ALDH (Fig. 3 D-F ), corresponding to H1650s bulk expression. Importantly, these single-cell observations matched our bulk analysis from Fig. 2 and Fig. S3 . Quantitative analysis of total gene expression, normalized by H1650 expression, indicated differential TERT and MET expression in WBCs and H1650 cells (P < 0.0001 for both cases, t test), indicating TERT and MET are both excellent markers to identify cancer cells compared with WBCs (Fig. 3E) . Average VIM and ALDH expression was similar between H1650 cells and WBCs, and H1650 expressed ALDH with higher variance (Fig. 3F ).
Multiplex Gene Expression Analysis of CTCs in NSCLC Cancer Patients.
Following a successful demonstration of multiplexed gene profiling of individual cancer cells from cell lines in spiked blood, we proceeded to analyze whole-blood samples from 55 human subjects (from June 2014 to August 2016). We analyzed blood from 20 healthy individuals from the Stanford Blood Center and 35 patients with stage IV NSCLC of adenocarcinoma histology to first identify CTCs by single-cell TERT and MET expression profiling, and second to determine whether these putative CTCs were abundant in NSCLC and not in healthy patients (Fig. 3 G and H and Table S1 ).
A representative stage IV Nanowell scan revealed a substantial number of nanowells with positive TERT and MET signal from single putative CTCs, whereas the healthy donor Nanowell exhibited negligible signals (Fig. 3G) . Putative CTCs were detected in almost all advanced-stage NSCLC samples, from 0 to 181 [interquartile range (IQR), (Fig. 3H) . In contrast, up to 7 positive wells out of 25,600 were detected in healthy controls (IQR, 2-6). Considering 7 or more putative CTCs in 2 mL as a positive sample, we detected putative CTCs in 31 of 35 (88.6%) patients. Because CellSearch detects clinically meaningful levels of CTCs in just 53% of patients with advanced-stage NSCLC (35) , our platform demonstrated higher capability to identify putative CTCs.
Interestingly, a stage III NSCLC patient blood sample revealed heterogeneity of expression across putative CTCs (Fig.  3I) . From each cell's multigene expression profile, a clear differentiation between putative CTCs and WBCs emerged, as predicted from the spike-in cell line experiments. Putative CTCs were identified by their high expression of both TERT and MET, whereas WBCs were identified by nanowells lacking TERT and Fig. 3 . Validation of our integrated nanoplatform with blood samples. (A) Workflow schematic of validation experiments. H1650 cells were spiked into whole-blood samples from healthy human subjects and processed through the MagSifter and Nanowell. (B) Scanned fluorescence images on Nanowell after RT-PCR amplification of four genes on the spike-in cells recovered using MagSifter. (Scale bar, 50 μm.) These genes were selected to identify putative CTCs (TERT and MET) and to demonstrate the multiplex capability of the assay using biologically informative targets (VIM and ALDH). Two major populations were visually observed: one with a primarily red color (C) and another with a primarily yellow color (D). (C) This cell population primarily expressed VIM and none of the other three assayed genes, which is characteristic of leukocytes (WBCs). (D) In contrast, a second cell population expressed TERT, MET, and VIM, and partially expressed ALDH, which is characteristic of H1650 cancer cells. (E) Quantitative analysis of Nanowell after RT-PCR exhibited a clear differentiation of TERT and MET expression levels between the cell populations in C and D (nominally WBCs and H1650 cells), with high statistical significance (P < 0.0001 for both cases, t test). (F) Quantitative analysis of VIM and ALDH expression revealed similar VIM expression between the two cell populations, whereas the ALDH expression in the latter cell population exhibited higher variance. (G) A two-channel fluorescence composite scan of the entire Nanowell array (25,600 wells) after on-chip RT-PCR using TERT and MET probes shows a stage IV NSCLC patient sample (Left), with a substantial number of TERT and MET positive wells. In contrast, the similar scan of a healthy donor blood sample (Right) lacked TERT and MET signal. MET expression and exhibiting high VIM expression. Variable VIM and ALDH expression was observed for putative CTCs (Fig. 3J) , which may reflect the heterogeneity of CTC populations present in lung cancer patients (36, 37) .
EGFR Mutation Detection in Single CTCs from NSCLC Patients. We then used our integrated nanoplatform to detect the most common and clinically relevant EGFR mutations (del19, L858R, and T790M) in CTCs from seven stage IV NSCLC adenocarcinoma patients who had known EGFR mutation status confirmed by tumor biopsy. Putative CTCs were assessed for three genes: TERT, the EGFR mutation (E746-A750del, L858R, or T790M), and the corresponding EGFR wild type (Fig. 4) . Because TERT gene exhibits superior distinction on cancer cell identification (Fig. 2) , putative CTCs were identified by high TERT expression. Notably, we were able to accurately detect each patient's known mutation from their putative CTCs (Fig. 4 B, D , and F), whereas the "bulk" RTqPCR measurements from the same patient's blood yielded undetectable levels of the assayed genes (Fig. 4 B and D) . Putative CTCs from E746-A750del visually appeared green (indicative of the EGFR mutation), whereas yellow (EGFR wild type) was nearly absent (Fig. 4A ). Quantitative analysis of putative CTCs confirmed that the majority of these were primarily EGFR mutant for del19, with very low wild-type EGFR expression (Fig. 4B ). Both L858R and the T790M de novo mutations were also detected via our integrated nanoplatform, revealing the heterozygous expression of both mutant and wild-type alleles (Fig. 4 C-F) . We further examined expression levels of EGFR mutations and their corresponding wild-type genes in CTCs from seven advanced NSCLC patients with known mutational statuses. Each putative CTC was identified by EGFR and TERT expression, and heterogeneous levels of EGFR expression across those CTCs were observed (Fig. 4G ).
Assay Performance Comparison. As shown in Fig. S4 , bulk PCR measurements performed directly on patients' whole blood yielded undetectable signals for EGFR mutations (del19 and others). Although EGFR wild type was found to be widely expressed from bulk assays of advanced-stage patients' blood, EGFR mutant genes were not. In addition, we assessed the analytical sensitivity of conventional PCR in vitro on NSCLC cell lines (HCC827 and H1650). Our data indicate that, although conventional PCR can reliably detect CTC-specific genes from a total of 100 cancer cells, this signal fluctuates significantly for 10 cells and is undetectable above background for <10 cells. Genes that were insufficiently expressed (e.g., ALDH, as in Fig. S5 ) were not detectable above threshold for samples of 10 or fewer cells. We also note that these experiments were performed on homogenized cell populations to extrapolate the number of cells in a sample, so this approach is expected to yield the most consistent and reliable serial dilution measurements. These observations confirm that conventional PCR cannot reliably assay "enriched" samples of cell populations of <10 or fewer cells, and hence a higher sensitivity approach is needed to reliably assay heterogeneous CTC populations for tumor-specific and therapy-relevant mutant gene panels.
To investigate mutational detection directly from enriched CTC population, we performed (i) a conventional PCR on extracted Fig. 4 . Multigene expression of CTCs from NSCLC patient blood samples (results from three of the seven patient samples that were analyzed for CTC gene mutation profiling are shown here). (A) Mutation detection assay on a stage IV NSCLC patient sample with EGFR del19 mutation previously confirmed by primary tumor biopsy and sequencing. Using a three-plex assay of TERT (Cy5, shown in blue), EGFR E746-A750del (FAM, shown in green), and EGFR wild type (HEX, shown in yellow), putative CTCs were identified by high TERT expression. (Scale bar, 50 μm.) (B) All TERT-positive wells (blue) exhibited EGFR mutant signal (green) and very low EGFR wild-type signal (yellow), indicating that putative CTCs were detected and identified as primarily EGFR del19 mutant. Subsequent quantitative analysis of TERT-positive wells confirmed the majority of identified putative CTCs were primarily EGFR del19 mutant. In addition, a few putative CTCs also exhibited some EGFR wild-type signal. (C) Nanowell scan of the EGFR L858R mutation assay on a stage IV NSCLC patient sample with EGFR L858R mutation. (D) Putative CTCs identified by their TERT expression exhibit heterozygous expression of both mutant and wild-type forms. (E) Nanowell scan of the EGFR T790M mutation assay of a stage IV NSCLC patient sample with de novo EGFR T790M mutation. (F) Putative CTCs demonstrate heterozygosity for the mutation. (G) Expression levels of EGFR mutations and their corresponding wild-type genes in CTCs from seven advanced NSCLC patients. Each CTC was identified by EGFR and TERT expression. Although heterogeneous levels of CTCs and patterns of EGFR expression across those CTCs were observed, follow-up work regarding these patients' clinical outcomes is necessary for proper heterogeneity analysis.
mRNAs from whole-blood samples of three advanced stage NSCLC patients, (ii) a conventional PCR on enriched CTCs by the MagSifter technology, and 3) our proposed MagSifter-Nanowell assay in a parallel manner, to compare their sensitivity. mRNAs from whole blood and from enriched CTCs were extracted using the TRIzol protocol described above. Two advanced-stage NSCLC patients with the EGFR del19 mutation, and an advanced-stage NSCLC patient with the EGFR T790M mutation were recruited for assay comparison. In all cases of mRNA analysis from whole blood and enriched CTCs, neither mutant genes (EGFR del19, and EGFR T790M) nor TERT were detected (Fig. S5) , whereas Nanowell could identify putative CTCs, which are either EGFR mutant, EGFR wild type, or both. This result agrees with our cell line experiment indicated above, thus showing the greater sensitivity of the Nanowell assay, especially when fewer numbers of CTCs are presented.
Additionally, to investigate Nanowell's performance against ICC, we recruited 11 NSCLC patients and 1 healthy donor to directly compare the signal positivity for immunostaining (CK (Table S2 ). Each patient's sample was split into two 2-mL samples for CTC assessment by both conventional enumeration (immunostaining) and Nanowell assay. Note that each 2 mL of patient blood was processed with MagSifter in parallel. Representative immunostained CTCs are illustrated in Fig. S2 . All resulting immunostained CTCs were confirmed by a Stanford Hospital pathologist. Enumeration results were positive for 3 of 11 cases (defined as CTC > 1), whereas the Nanowell assay measured positive signals above threshold for 8 of 11 cases, as shown in Table 1 (the full analysis is given in Table S2 ). These observations indicate the higher sensitivity of our approach, which is because of the signal amplification by PCR. We note that the 11 patients enrolled in this study spanned all lung cancer stages, representing early-stage tumors that are thought to release low numbers of CTCs and those more advanced tumors that are expected to release more CTCs.
Discussion
Our integrated nanoplatform is a high-throughput, massively parallel CTC enrichment and subsequent molecular characterization tool for tumor biology and, potentially, for clinical use as a diagnostic/prognostic tool (38) . It achieves accurate identification of hundreds to thousands of putative CTCs with multiplex gene mutation profiling capabilities. Each of the 25,600 nanowell compartments are 20 × 20 × 50 μm 3 , with 20-pL volumes that are 10 6 times smaller than those of typical PCR assays, thereby enabling higher sensitivity from higher mRNA concentrations. To this point, we observed that conventional RT-PCR assays of mRNA extracted from patients' blood yielded undetectable TERT expression for all samples and no MET expression for 76% of patient samples (Fig. S4) . Nanowell assays also achieve excellent specificity by using hydrolysis probes (e.g., TaqMan).
Detection of EGFR mutations, such as del19, L858R, and T790M, in lung cancer is now proving critical to inform clinical treatment decisions with EGFR tyrosine kinase inhibitor (TKI) therapies (39) . Because 15% of lung adenocarcinomas harbor EGFR mutations-a number that is at least twice as high in the Asian population-many patients undergoing treatment in clinics for whom biopsy material is difficult to obtain may not be receiving optimal therapy. Furthermore, because resistance inevitably develops in patient with EGFR driver mutations that are treated over 12-24 months, and currently this can be monitored only by imaging and clinical gestalt, blood biomarkers for disease monitoring are desperately needed to guide management. Circulating tumor DNA (ctDNA) is a promising avenue to guide therapy, but recent data suggest that CTCs may be a complementary, rather than extraneous, approach (40) . For example, ctDNA analysis from a del19 patient (Fig. 4A ) using cancer personalized profiling by deep sequencing (41) (CaPP-Seq) detected del19 mutation at an allele frequency of 3.12%, indicating nontrivial tumor burden with this particular mutation.
Additionally, recent studies have demonstrated the promising potential of next-generation sequencing (NGS) profiling of CTCs (29, 42) , especially to inform prognostic assessment and precise personalized cancer treatment (43) . Unfortunately, widespread adoption of NGS for single-CTC sequencing is currently hindered by high costs and technical complexity for extracting clinically actionable information. Our integrated nanoplatform has the advantages of lower cost (with reagent costs of ∼25 US dollars per assay) and fast sample-to-answer time (Table S3) given its targeted strategy. Nonetheless, we believe NGS is a powerful tool that will become more cost-effective over time, and we envision using the Nanowell as a validation tool to confirm targets on CTCs discovered by whole-genome approaches.
The modular nature of our multiplex assay using "off-theshelf" commercial reagents provides versatility for exploring research questions on individual CTCs and acts as a valuable tool for CTC analysis. As an example, we have demonstrated heterogeneous expression of ALDH and VIM on putative CTCs in this study. Cell immortality and plasticity defined by these types of expression markers are well established to be important in cancer progression. Exactly how this type of CTC heterogeneity affects patient outcome and relates to imaging and clinical parameters is an important, and incipient, avenue of inquiry that should be pursued by research laboratories in the field.
The technology reported here requires further optimization before widespread application in clinical settings. First, comprehensive enrichment of an entire population of heterogeneous CTCs requires the use of multiple capture antibodies. Although our platform currently relies on EpCAM enrichment, the Nanowell assay is highly sensitive and specific to tumor-derived cells neglected by ICC (Fig. S2) . Moreover, MagSifter can be generalized to accommodate multiple cell capture antibodies instead of, or in conjunction with, EpCAM. This approach would broaden the platform's utility to many other cancers that shed CTCs [e.g., human epidermal growth factor receptor (HER2) for breast cancer, neuron-glial antigen 2 (NG2) for melanoma, and carbonic anhydrase IX (CAIX) for renal cell carcinoma] and to EpCAM-low and EpCAM-negative populations. Second, our platform currently employs up to four fluorophores for multiplex single-cell gene expression profiling, because primer-probe sets are only commercially available in four discrete excitationemission spectra that can be resolved by conventional fluorescence microscopy. However, further modifications, including I  2  21  4  NSCLC  II  3  15  1  NSCLC  I  4  14  6  NSCLC  I  5  11  0  NSCLC  III  6  9  0  NSCLC  II  7  9  0  NSCLC  I  8  9  0  NSCLC  IV  9  7  0  NSCLC  I  10  7  7  NSCLC  IV  11  7  0  NSCLC  II  12  0  0  Healthy  N/A Markedly, the Nanowell assay's analytical sensitivity exceeded that of conventional ICC for putative CTC detection in NSCLC patients. More information can be found in Table S2 .
laser excitation, sharper bandpass filters, and narrower-emission hydrolysis probes, may extend the platform's multiplex capability to accommodate 12 or more genes (26) . This expansion will allow comprehensive mutational profiling to develop along with clinical advances to capture a comprehensive panel of relevant "actionable" mutations for therapy selection and disease monitoring. We also envision that the Nanowell as a clinical research tool to study (i) the assessment of heterogeneity across CTCs with patient's clinical outcomes, (ii) lineage mapping studies of biopsied primary tumor cells, (iii) correlation studies with cellfree and ctDNA, and (iv) discrimination between benign and malignant states for early cancer detection.
Materials and Methods
Patient Samples and Clinical Data. All patient-related research was approved by the Stanford Institutional Review Board before study initiation and informed consent was obtained from the participants. For each patient, samples of whole blood were drawn into 10-mL Vacutainer K 2 -EDTA tubes (Becton Dickinson), and sample ID numbers were assigned to anonymize clinical identification. Healthy human blood samples were obtained from the Stanford Blood Center (Palo Alto, CA), and patient blood samples were drawn from those with NSCLC from Pulmonary, Medical Oncology, and Radiation Oncology Clinics at Stanford University Medical Center. Healthy donor samples were used for our spike-in experiments with cell lines and as negative controls, whereas patient blood samples were processed for CTC identification and mutation detection. Lung cancer diagnoses were extracted from the medical record, and we defined advanced-stage NSCLC here as stage IV by the American Joint Committee on Cancer (AJCC-7) staging criteria.
Some NSCLC patient samples were plasma depleted for other research purposes and then resuspended with an equal volume of 1× Gibco PBS buffer (Life Technologies). All blood samples were processed as soon as possible after blood draw (within 1-24 h). For each 7.5-mL blood sample, 2 mL was processed with the MagSifter and ICC for CTC enumeration, 2 mL was independently processed with the integrated nanoplatform for single-CTC gene expression and mutation analysis, and the remaining volume was allocated for total mRNA extraction via a TRIzol protocol for bulk gene expression analysis.
Nanowell Processing. Following CTC enrichment by MagSifter and treatment of the eluent with lysis buffer and DNase, the entire eluent was loaded into an assembled Nanowell array (Fig. S1D) , by centrifugation at 3,000 rpm for 10 min. Because each Nanowell array contains 25,600 wells and the CTC population from 2 mL of blood is expected to be no more than 2,000 cells, each individual well has a 99.7% chance of containing either a single cell or no cell, according to the Poisson distribution (Table S4) , and only a 0.3% of containing two or more cells, thereby representing a high-throughput method of analyzing "single" cells. Identification of putative CTCs was then performed as follows. First, fluorescence microscope images of the entire Nanowell array were acquired for identification and exclusion of wells containing WBCs by CD45 signal. Next, the entire Nanowell array was completely dried at 70°C for 10 min to fix seeded cells into the wells and to completely deactivate the DNase. Then, an RT-PCR master mix was applied, and the array was centrifuged for nanowell seeding at 3,000 rpm (Sorvale Legend RT Centrifuge; Thermo Fisher Scientific) for 10 min. The RT-PCR master mix consisted of 2× reaction mix (CellsDirect One-Step qRT-PCR; Life Technologies), polymerases (SuperScript III RT/Platinum Taq Mix; Life Technologies), TaqMan probes (Life Technologies; Bio-Rad) for targeting specific genes, and diethylpyrocarbonate (DEPC)-treated water (for detailed quantities, see Table S5 ). To prevent water evaporation during PCR thermocycling, the array was then capped with a small piece of adhesive PCR sealant film (Bio-Rad) and centrifuged at 3,000 rpm for 10 min, and white mineral oil (W. S. Dodge Oil) was applied around the array edges. The array was then loaded into a thermal cycler (PTC-200; Peltier Thermal Cycler; Bio-Rad) using the following cycle parameters: for the first thermal cycler step, cell lysis and subsequent reverse transcription, the array was incubated at 50°C for 45 min. This was followed by 10 cycles of 60 s at 95°C for denaturation and 90 s at 65°C for an annealing and extension step. Amplification commenced after with 35 cycles of 60 s at 90°C and 90 s at 60°C. Nanowell Signal Acquisition. For all Nanowell assays, automated scanning of the full array was performed at Stanford University's Cell Science Imaging Facility (CSIF) on a Zeiss Axio Imager fluorescence microscope (Carl Zeiss) with Zeiss ZEN Pro software. Each Nanowell was imaged for FAM, HEX, Texas Red, and Cy5 fluorescence after single-cell RT-PCR with a ZEISS Axiocam 503 monochrome camera. For each Nanowell, 100 regions of the array were imaged at 10× magnification, and images were stitched together with ZEN Pro software.
Marker Gene and Fluorophore Selection. We reviewed the biomedical literature using the search terms "circulating tumor cell," "lung cancer," and "blood" in MEDLINE to identify potential biomarkers for single-cell expression analysis of CTCs. We identified about 400 articles pertaining to lung cancer CTCs, and from this literature, we identified TERT (29, 30, (44) (45) (46) (47) (48) and MET (31, 32, 49-52) as promising marker genes for the CTC identification panel. TERT is up-regulated by many oncogenes, and overexpression of TERT is well established as dysregulated in cancers. TERT is required for the perpetuation of the malignant clone during cancer progression as it elongates telomeres in each cell division, but is not expressed in normal somatic cells. Similarly, hepatocyte growth factor receptor (HGFR), or MET, is a proto-oncogene whose up-regulation is closely associated with NSCLC. Similarly, we reviewed the literature and identified VIM and ALDH as promising marker genes for the heterogeneity panel. VIM is an epithelial-mesenchymal transition (EMT) marker, whose expression indicates the increased potential for tumor metastasis (36) . Multiple markers of cancer cell stemness exist, but we chose ALDH as a marker that indicates tumorigenicity and clonogenicity of lung cancer (37) based on commercially available primer-probe sets. Finally, for the therapy prediction and monitoring panel, we selected EGFR E746-A750del mutation, its associated wild-type gene, and TERT. Other clinically relevant EGFR mutations, including L858R and T790M, can also be included as needed. Each marker was assigned a specific fluorescence channel: FAM (492-nm excitation, 517-nm emission) to TERT, HEX (530-nm excitation, 556-nm emission) to MET, Texas Red (596-nm excitation, 615-nm emission) to VIM, and Cy5 (650-nm excitation, 670-nm emission) to ALDH.
Four-Gene Expression Development. Simultaneous gene expression measurement of two genes in the Nanowell array was previously reported (26) . To extend this capability to accommodate four-plex gene expression analysis on a single cell, the procedure was optimized to avoid issues of reagent depletion and weaker signal for lower-expressing genes (53) . We selected probes with four different fluorophores and minimal spectral overlap for simultaneous four-plex gene expression capability. The four fluorophores, FAM, HEX, Texas Red, and Cy5, had excitation and emission peaks of 492 and 517 nm, 530 and 556 nm, 596 and 615 nm, and 650 and 670 nm, respectively. Primer-probe assays were obtained commercially: TERT (Life Technologies), MET (Life Technologies), VIM (Bio-Rad), and ALDH (Bio-Rad). The four-plex RT-PCR process was optimized on conventional bulk assay in a CFX96 Touch Real-Time PCR Detection System (Bio-Rad).
Statistical Analysis. After single-cell RT-PCR and fluorescence image acquisition were performed, custom-developed MATLAB and R scripts were used to analyze signals from the Nanowell arrays. For the diagnosis of NSCLC patients with Nanowell assays for TERT and MET, the following protocol was performed. Bright-field images acquired before and after single-cell RT-PCR were first manually inspected for the pixel locations of the Nanowell array at the top left, top right, and bottom left of the image area to be analyzed. These pixel locations were entered into a MATLAB script that extracted the pixel spacing information for the Nanowell array by using its natural periodicity. The script then used this periodicity to extrapolate the location of each nanowell within the image area of interest, and extracted the pixel intensities within each nanowell for every fluorescence channel of interest. As successful amplification in a nanowell results in an extremely bright spot within the nanowell, it was determined that a metric comparing the dispersion of pixel intensities within each nanowell could determine whether amplification had successfully occurred. Thus, a custom R script was used to run an outlier detection algorithm for each fluorescence image, whereby a z score for the variance in pixel intensity within each nanowell was computed to determine the probability of each individual point being an outlier from the entire population. Due to the large number of nanowells in each population (typically >5,000 per image analyzed), the central limit theorem dictates that the distribution should follow a normal distribution, thus allowing use of the Z test to identify outliers at a significance level of P < 0.05. Additionally, due to the large number of points tested per image, Bonferroni correction was performed when conducting the Z test to avoid excessive type I errors, with the Bonferroni correction commonly regarded as one of the most conservative ways to control familywise error rates. The R script then computed a count for the nanowells with z scores above this threshold and classifies these nanowells as positive for the particular measurement. The images in the individual fluorescence channels were analyzed separately, and the nanowell counts were then collated either individually (as in the PE-fluorescence image pre-RT-PCR when excluding nanowells with WBCs) or together (as per the use of both FAM and HEX channel images when enumerating potentially cancerous entities after RT-PCR). For all analysis of images acquired by the Zeiss Axio Imager, including the EGFR mutation assay and the four-marker gene expression panel, individual nanowell fluorescence intensities were extracted from ZEN Pro for each channel and collated manually after subtraction of background intensities from the empty nanowells.
Identification of Putative CTCs. In this study, "putative CTCs" are mostly defined as cells with the multigene signature having high expression in both TERT and MET genes. This multigene approach yields the best assay performance (compared with a single-gene assay of either TERT or MET) by minimizing the frequency of "false positives" that are acquired because of intrinsic and extrinsic sources of background noise. In addition, for mutational detection purposes, we define putative CTCs as cells having either TERT and an EGFR mutation gene, or TERT and the corresponding EGFR wild-type gene. Transcriptomic profiles of putative CTCs are stable up to 12 hours from the blood draw (Fig. S6) .
